Winners Announced in Prestigious GCCA Photo Competition Which Highlights Beauty and Essential Role of Concrete Throughout World
A stunning image of a skateboard park in the United Arab Emirates has been named Concrete in Life Photo of the Year. It wins a top prize of $10,000 (ten thousand US dollars) in a global competition, which highlights the essential role that concrete plays around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230215005136/en/
Ferdz Bedana, winner Urban Concrete Professional and overall winner, Concrete in Life Photo of Year. Location Sharjah, UAE
The photo, taken by professional photographer, Ferdz Bedana, in Sharjah, was announced as the overall winner in a live Instagram broadcast, on 15th February. It was selected from more than 14,000 photos submitted by both amateur and professional photographers from every continent, in the annual competition run by the Global Cement and Concrete Association.
Thomas Guillot, GCCA Chief Executive said: “Concrete is the second most used substance on earth after water and plays a vital part in modern infrastructure and society. Through the work of the GCCA and our members, to implement our 2050 Net Zero Roadmap, we are working hard and making progress in reducing its environmental impact. These amazing photos capture the appeal of concrete design and the essential role it plays in modern life and communities everywhere.”
Entrants from around the world submitted photos across four categories: concrete infrastructure, concrete beauty and design, urban concrete, and concrete in daily life, with each section divided between professional photographers and amateurs, often with smart phones. The breadth and variety of all the entries highlight the way concrete supports life around the world, from the giant to the small form, as well as the material’s grace, beauty and crucial supporting role.
Eight category winners each receive a prize of $2,500 (two thousand, five hundred US dollars) each. As well as Ferdz Bedana’s skateboarder image, the category winners include images of a waterfall and a roller-skater race, both taken in Indonesia, a stunning city interchange in China, rice mills in Bangladesh, a university building in Mexico, a metro station in Dubai and a Mosque in Istanbul, Turkey.
Ferdz Bedana who took the overall Concrete in Life Photo of Year in Sharjah, said: “It’s a great honour to be the overall winner of the Concrete in Life 2022 competition and spread the story of how concrete is a big contribution in our life. I was interested to take a photo of this skatepark when I saw a boy enjoying playing in a substantially artistic concrete design.”
Chris George, Content Director at Digital Camera World, and one of the competition judges said about the winning photo: “This was an amazing capture, that perfectly shows the energy of skateboarding against the organic form of the manmade structure.”
Fellow judge, freelance writer and photographer Norman Miller added: “It’s a real skill to capture fast moving subject while showing mastery of framing and control of lighting.”
Thomas Guillot, GCCA Chief Executive added: “Congratulations to Ferdz Bedana and all our category winners. Check out our website to see all the shortlisted entries who were all outstanding.”
The GCCA and its member companies, which account for 80% of global cement production capacity outside of China, as well as key Chinese manufacturers, are committed to reducing and eliminating CO2 emissions through implementation of the Concrete Future - 2050 Net Zero Roadmap – the first heavy industry to set out such a detailed plan.
Notes to editors:
Images available for media to use here .
Video of Instagram broadcast announcing winners available here .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230215005136/en/
Contact information
For further details, or interview requests:
Simon Thomson, Head of Media, GCCA
simon.thomson@gccassociation.org / +44 7380 972282
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
